Editorial Comment to Progressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: An autopsy case report

Affiliations

Editorial

Tetsutaro Hayashi et al. IJU Case Rep. 2020.

. 2020 Jun 28;3(5):169-170.

doi: 10.1002/iju5.12183. eCollection 2020 Sep.

¹ Department of Urology Institute of Biomedical and Health Sciences Integrated Health Sciences Hiroshima University Hiroshima Japan.

No abstract available

Conflict of interest statement

The authors declare no conflict of interest.

1. Kohada Y, Kaiho Y, Ito J et al. Progressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: an autopsy case report. IJU Case Rep. 2020; 3: 166–9. - PMC - PubMed
1. Simon C, Skala S, Killen P et al Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. Diagn. Pathol. 2019; 14: 113. - PMC - PubMed
1. Al‐Ahmadie H, Iyer G, Lee B et al Frequent somatic CDH1 loss‐of‐function mutations in plasmacytoid‐variant bladder cancer. Nat. Genet. 2016; 48: 356–8. - PMC - PubMed
1. Kim B, Kim G, Song B et al HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder. Dis. Markers 2016; 2016: 8463731. - PMC - PubMed
1. Hayashi T, Seiler R, Oo HZ et al Targeting HER2 with T‐DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J. Urol. 2015; 194: 1120–31. - PubMed